← Leaderboards
Jon Mirasilas
Sri International
$3,865,057
Attributed
$3,865,057
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2022–24$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
Funding mix
By agency
NIH$3,865,057 · 1
By mechanism
N01$3,865,057 · 1
Top collaborators
No co-investigators on record.
Most similar at Sri International
Same institution · by research overlap
- Jon Carl Mirsalis$108,012,322
- Jon Mirsalis$56,020,705
- Katherine Baughman$4,521,467
- Toufan Parman$25,866,968
- Carol E Green$19,982,282
Others in their field
Other Rising Stars on “Product Development”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Gary Mays · Axle Informatics, Llc$31,128,888
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Walt Lee$25,884,232
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
Research focus
Product DevelopmentSafetyServicesDrug KineticsEvaluationInterventional Agent DevelopmentIn VitroIn VivoLeadChemistryPathogenPre-ClinicalProgramsCommunicable DiseasesToxicologyToxinDevelopment PlansTherapeutic DevelopmentBiologicalManufactureStaphylococcus AureusToxic EffectAntibiotic ResistanceAntimicrobial Resistance
Grant awards (12)
Task D16: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases$1,568,951
N01 · FY2024 · AI · contact PI
Task D16: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases$666,515
N01 · FY2024 · AI · contact PI
Task D17: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases$260,145
N01 · FY2024 · AI · contact PI
Task C23: Continuation of Oxfendazole Stability Studies$63,336
N01 · FY2024 · AI · contact PI
Task D16: Nonclinical Services for the Development of Interventional Agents for Antibiotic Resistant Infectious Diseases$45,786
N01 · FY2024 · AI · contact PI
Task A07: Updating Generic Version of Product Development Plan for Monoclonal Antibodies$24,845
N01 · FY2024 · AI · contact PI
Task A07: Updating Generic Version of Product Development Plan for Monoclonal Antibiotic-Resistant Antibodies$24,844
N01 · FY2024 · AI · contact PI
Task B29: NONCLINICAL SERVICES FOR THE DEVELOPMENT OF INTERVENTIONAL AGENTS FOR INFECTIOUS DISEASES$115,733
N01 · FY2023 · AI · contact PI
TO D12 NHPCOLONY MAINTENANCE$97,439
N01 · FY2023 · AI · contact PI
Task D9: Exploratory Tolerability Toxicity Studies$59,143
N01 · FY2023 · AI · contact PI
Task C16: APP Manufacture of Products$495,500
N01 · FY2022 · AI · contact PI
Task D9: Exploratory Tolerability/Toxicity and GLP Toxicity Studies$442,820
N01 · FY2022 · AI · contact PI